通脉养心丸通过m6A/ALKBH5/BNIP3轴改善多柔比星心脏毒性
本研究探讨通脉养心丸是否通过m6A依赖性机制改善多柔比星(DOX)心脏毒性。体内实验显示通脉养心丸改善心脏功能与线粒体功能;体外实验显示其通过ALKBH5/m6A依赖方式降低BNIP3 mRNA稳定性,恢复线粒体能量代谢,减轻心肌细胞凋亡。
要点
- 通脉养心丸可改善DOX处理后的心脏功能与线粒体功能。
- 通脉养心丸通过ALKBH5/m6A轴降低BNIP3 mRNA稳定性。
- 通脉养心丸减轻DOX诱导的心肌细胞凋亡。
核心结论
- 通脉养心丸通过改善心肌细胞线粒体能量代谢,对DOX诱导的心脏毒性发挥保护作用。
- 该保护作用与ALKBH5/m6A依赖性地抑制BNIP3 mRNA稳定性相关。
研究设计与样本
- 体内实验观察通脉养心丸对DOX心脏毒性的保护作用。
- 体外采用CCK-8、JC-1荧光线粒体膜电位分析、ROS荧光、TUNEL assay和氧消耗率测定评估通脉养心丸对DOX处理心肌细胞的保护作用。
主要发现
- 体内通脉养心丸给药有效改善心脏功能并恢复线粒体功能。
- 体外通脉养心丸通过恢复被DOX抑制的线粒体能量代谢减轻心肌细胞凋亡。
- 通脉养心丸降低DOX处理心肌细胞的m6A甲基化水平并促进m6A去甲基化酶ALKBH5表达。
- 通脉养心丸以ALKBH5/m6A依赖方式抑制BNIP3 mRNA稳定性,改善心肌细胞线粒体能量代谢。
临床怎么用
- 通脉养心丸作为中药复方改善DOX心脏毒性具有潜在保护作用。
- 其作用机制涉及m6A/ALKBH5/BNIP3轴,为中药复方治疗心脏毒性提供新视角。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Cardiotoxicity caused by doxorubicin (DOX) has become the most important toxicity that hinders its clinical application. Tongmai Yangxin (TMYX) Pill is a Chinese patent medicine composed of the ancient classic prescriptions Zhiguorice decoction and Shengmai powder. AIM OF THE STUDY: The present study aimed to investigate whether and how TMYX ameliorated the DOX-induced cardiotoxicity via an m6A-dependent mechanism. MATERIALS AND METHODS: CCK-8, JC-1 fluorescence mitochondrial membrane potential analysis, ROS fluorescence, TUNEL assay, and oxygen consumption rate assays were performed to evaluate the protective effects of TMYX on cardiomyocytes which were treated with DOX. RESULTS: In vivo, TMYX administration effectively improved cardiac function and restored mitochondrial function. For the cardiomyocytes in vitro, TMYX alleviated the cardiomyocytes' apoptosis by recovering mitochondrial energy metabolism that was repressed by DOX treatment. Besides, TMYX reduced the m6A methylation level and promoted m6A demethylase ALKBH5 expression in DOX-treated cardiomyocytes. Mechanistically, TMYX repressed the BNIP3 mRNA stability in an ALKBH5/m6A-dependent manner to improve cardiomyocytes mitochondrial energy metabolism. CONCLUSION: These findings illustrated a remarkable protective role of TMYX against DOX-induced cardiotoxicity through ameliorating cardiomyocyte mitochondrial energy metabolism, which provided a new perspective for the mechanism of Chinese medicine compound in the treatment of cardiotoxicity.
引用
- Zhao W, Wu Y, Li Y, et al. Tongmai Yangxin Pill ameliorates doxorubicin-induced cardiotoxicity through m6A/ALKBH5/BNIP3 axis. J Ethnopharmacol. 2026. PMID: 41554447. doi:10.1016/j.jep.2026.121213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。